BiotechTube

FR104

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Kidney Transplantation

Conditions

Kidney Transplantation

Trial Timeline

Jun 28, 2021 → Apr 14, 2025

NCT ID
NCT04837092

About FR104

FR104 is a phase 1/2 stage product being developed by OSE Immunotherapeutics for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT04837092. Target conditions include Kidney Transplantation.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04837092Phase 1/2Completed

Competing Products

20 competing products in Kidney Transplantation

See all competitors
ProductCompanyStageHype Score
Empagliflozin + Matching placeboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
SGLT2 inhibitorEli LillyPre-clinical
23
LY2623091 + EplerenoneEli LillyPhase 2
52
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
85
TacrolimusAstellas PharmaApproved
85
RituximabAstellas PharmaPhase 2
52
Prograf + MR4Astellas PharmaPhase 3
77
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
85
Tacrolimus, modified releaseAstellas PharmaPhase 3
77
Tacrolimus granulesAstellas PharmaApproved
85
roxadustatAstellas PharmaPhase 3
77
Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved
85
ASP1128 + PlaceboAstellas PharmaPhase 2
52
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + PrednisoloneAstellas PharmaPhase 3
77
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
85
ASP1585Astellas PharmaPhase 3
77
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + CorticosteroidsAstellas PharmaPhase 2
52
Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved
85
tacrolimusAstellas PharmaApproved
85

Other Products from OSE Immunotherapeutics

OSE2101 + DocetaxelPhase 3
69
OSE2101 + Docetaxel + PemetrexedPhase 3
69
OSE-127 + PlaceboPhase 2
44
FOLFIRI + OSE2101Phase 2
44
Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negativePhase 1/2
33